ZA962336B - Reversible protease inhibitors - Google Patents

Reversible protease inhibitors

Info

Publication number
ZA962336B
ZA962336B ZA962336A ZA962336A ZA962336B ZA 962336 B ZA962336 B ZA 962336B ZA 962336 A ZA962336 A ZA 962336A ZA 962336 A ZA962336 A ZA 962336A ZA 962336 B ZA962336 B ZA 962336B
Authority
ZA
South Africa
Prior art keywords
protease inhibitors
reversible protease
reversible
inhibitors
protease
Prior art date
Application number
ZA962336A
Other languages
English (en)
Inventor
James T Palmer
David Rasnick
Jeffrey Lee Klaus
Original Assignee
Arris Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharmaceutical filed Critical Arris Pharmaceutical
Publication of ZA962336B publication Critical patent/ZA962336B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA962336A 1995-03-24 1996-03-22 Reversible protease inhibitors ZA962336B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
ZA962336B true ZA962336B (en) 1996-07-31

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA962336A ZA962336B (en) 1995-03-24 1996-03-22 Reversible protease inhibitors

Country Status (15)

Country Link
EP (1) EP0817778A1 (xx)
JP (1) JPH11503417A (xx)
KR (1) KR19980703261A (xx)
CN (1) CN1071751C (xx)
AU (1) AU713492B2 (xx)
CA (1) CA2216151A1 (xx)
CZ (1) CZ298197A3 (xx)
IL (1) IL117638A0 (xx)
MY (1) MY113489A (xx)
NO (1) NO311573B1 (xx)
NZ (1) NZ305626A (xx)
PL (1) PL322409A1 (xx)
TW (1) TW470750B (xx)
WO (1) WO1996030353A1 (xx)
ZA (1) ZA962336B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251714A1 (en) 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
CZ29799A3 (cs) * 1996-07-30 1999-06-16 Arris Pharmaceutical Corporation Disubstituovaná cyklická sloučenina, způsob její výroby, farmaceutický přípravek a způsob léčení onemocnění živočicha
DE19817461A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
EP1218372B1 (en) * 1999-09-13 2003-07-02 Boehringer Ingelheim Pharmaceuticals, Inc. Novel heterocyclic compounds useful as reversible inhibitors of cysteine proteases
AU784746B2 (en) 1999-11-18 2006-06-08 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
AU8125501A (en) 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
WO2002014315A2 (en) 2000-08-14 2002-02-21 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
AU2001288714A1 (en) 2000-09-06 2002-03-22 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
AU2002232558A1 (en) * 2000-12-12 2002-06-24 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
MXPA03005601A (es) 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
CN1324008C (zh) * 2001-09-14 2007-07-04 安万特药物公司 作为组织蛋白酶抑制剂的新化合物和组合物
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
WO2003042197A1 (en) 2001-11-14 2003-05-22 Aventis Pharmaceuticals Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
CN102105485B (zh) * 2008-05-21 2016-01-13 新世界实验室公司 选择性胱天蛋白酶抑制剂及其用途
WO2010133000A1 (en) 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
WO2011069149A2 (en) 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
CA2833082C (en) 2011-04-15 2019-12-31 New World Laboratories, Inc. Selective cysteine protease inhibitors and uses thereof
KR101309578B1 (ko) * 2011-05-06 2013-09-17 연세대학교 산학협력단 시스테인 프로테아제 선택성을 갖는 다이타이로신 화합물 및 이를 이용한 시스테인 프로테아제의 검출방법
KR101385855B1 (ko) * 2012-10-16 2014-04-22 이동익 카뎁신 검출용 다이아로마틱 아미노산 기질
WO2019142890A1 (ja) * 2018-01-19 2019-07-25 株式会社大阪ソーダ 有機珪素化合物、及びそれを用いたゴム組成物
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
AU5367496A (en) 1996-10-16
AU713492B2 (en) 1999-12-02
EP0817778A1 (en) 1998-01-14
WO1996030353A1 (en) 1996-10-03
NO974403D0 (no) 1997-09-23
KR19980703261A (ko) 1998-10-15
CZ298197A3 (cs) 1998-03-18
JPH11503417A (ja) 1999-03-26
CN1071751C (zh) 2001-09-26
NO974403L (no) 1997-11-17
MY113489A (en) 2002-03-30
TW470750B (en) 2002-01-01
NZ305626A (en) 2000-01-28
IL117638A0 (en) 1996-07-23
CA2216151A1 (en) 1996-10-03
PL322409A1 (en) 1998-01-19
CN1184472A (zh) 1998-06-10
NO311573B1 (no) 2001-12-10

Similar Documents

Publication Publication Date Title
ZA962336B (en) Reversible protease inhibitors
PL326508A1 (en) Protease inhibitors
ZA964751B (en) Reversible cysteine protease inhibitors
PL336625A1 (en) Protease inhibitors
HU9601508D0 (en) Dp-iv-serine protease inhibitors
EP0744948A4 (en) PROTEASE INHIBITORS
PL336589A1 (en) Serinic protease inhibitors
HUP9903863A3 (en) Metalloproteinase inhibitors
PL328307A1 (en) Serinic protease inhibitors
HUP0002247A3 (en) Protease inhibitors
ZA983841B (en) Protease inhibitors
IL132629A0 (en) Protease inhibitors
PL328875A1 (en) Serinic protease inhibitors
ZA988479B (en) Protease inhibitors
PL328223A1 (en) Aspartil protease inhibitors
HUP9802764A3 (en) Guanidino protease inhibitors
ZA988064B (en) Protease inhibitors
ZA961225B (en) Serine protease inhibitors
EP0975612A4 (en) PROTEASE INHIBITORS
GB9520761D0 (en) Protease inhibitors
GB9500946D0 (en) Protease inhibitors
GB2318353B (en) Metalloproteinase inhibitors
GB9420277D0 (en) Protease inhibitors
GB9503754D0 (en) Metalloproteinase inhibitors
GB9506107D0 (en) Metalloproteinase inhibitors